We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Software Tool Identifies Driver Genes and Pathways in Cancer Sequencing Studies

By LabMedica International staff writers
Posted on 03 Sep 2013
Cancer researchers have developed a software tool that enables them to identify the driver mutations that underlie the transformation of normal cells and tissues into malignancies.

Cancers are caused by the accumulation of genomic alterations. More...
Driver mutations are required for the expression of a cancer phenotype, whereas passenger mutations are irrelevant to tumor development and accumulate through DNA replication. A major challenge facing the field of cancer genome sequencing has been identifying cancer-associated driver gene mutations.

Investigators at the Medical College of Wisconsin (Milwaukee, USA) have described a powerful and flexible statistical framework for identifying driver genes and driver signaling pathways in cancer genome-sequencing studies. Biological knowledge of the mutational process in tumors was fully integrated into their statistical models, which included such variables as the length of protein-coding regions, transcript isoforms, variation in mutation types, differences in background mutation rates, the redundancy of genetic code, and multiple mutations in one gene.

A detailed description of the software tool, which was nicknamed DrGaP—for Driver Genes and Pathways—was published in the August 15, 2013, online edition of the American Journal of Human Genetics.

"DrGaP is immediately applicable to cancer genome sequencing studies and will lead a more complete identification of altered driver genes and driver signaling pathways in cancer," said senior author Dr. Pengyuan Liu, associate professor of physiology at the Medical College of Wisconsin. "Biological knowledge of the mutation process is fully integrated into the models, and provides several significant improvements and increased power over current methods."

Related Links:
Medical College of Wisconsin



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.